comparemela.com
Home
Live Updates
Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer : comparemela.com
Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer
/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) ("Fusion"), a clinical-stage oncology company focused on developing next-generation targeted alpha...
Related Keywords
Boston ,
Massachusetts ,
United States ,
Deerfield ,
Canada ,
Canadian ,
Ebrahim Delpassand ,
John Valliant ,
Amanda Cray ,
Fusion Pharmaceuticals Inc ,
Morgan Stanley ,
Spica Center ,
Deerfield Management Company ,
Nasdaq ,
Laborde Professor For Cancer Research ,
Astrazeneca ,
Prnewswire Fusion Pharmaceuticals Inc ,
Radiomedix Inc ,
Fusion Pharmaceuticals ,
Woodline Master Fund ,
Niowave Inc ,
Tulane Cancer Center ,
Exchange Commission ,
Diagnostics Nuclear Oncology Center ,
Investor Relations Corporate Communications ,
Fusion Chief Executive Officer John Valliant ,
Laborde Professor ,
Cancer Research ,
Medical Director ,
Tulane Cancer ,
Excel Diagnostics ,
Nuclear Oncology ,
Avidity Partners ,
Federated Hermes Kaufmann Funds ,
Perceptive Advisors ,
Securities Act ,
Targeted Alpha Therapy ,
Response Inhibitors ,
Private Securities Litigation Reform Act ,
Investor Relations ,
comparemela.com © 2020. All Rights Reserved.